Search

Royalty Pharma PLC (Class A)

Затворен

СекторЗдравеопазване

58.45 0.1

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

58.17

Максимум

58.52

Ключови измерители

By Trading Economics

Приходи

-589M

-295M

Продажби

44M

674M

P/E

Средно за сектора

31.747

56.432

EPS

1.32

Дивидентна доходност

1.55

Марж на печалбата

-43.713

Служители

100

EBITDA

-387M

176M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+12.51% upside

Дивиденти

By Acuity

Дивидентна доходност

Средно за сектора

1.55%

2.27%

Следващи печалби

4.11.2026 г.

Следваща дата на дивидент

9.12.2026 г.

Следваща дата на екс-дивидент

13.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.2B

34B

Предишно отваряне

58.35

Предишно затваряне

58.45

Настроения в новините

By Acuity

15%

85%

7 / 339 Класиране в Healthcare

Royalty Pharma PLC (Class A) Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.09.2026 г., 20:06 ч. UTC

Royalty Pharma PLC shares fell sharply on Friday, closing significantly below its 20-day moving average and near the lower end of its one-month range.

17.09.2026 г., 23:06 ч. UTC

Royalty Pharma PLC declined in after-market trading, moving lower since Thursday's close and positioning it below its 20-day moving average.

16.09.2026 г., 23:06 ч. UTC

Royalty Pharma PLC is trading lower in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

15.09.2026 г., 23:16 ч. UTC

News

Royalty Pharma announced a $7.5 million donation to Blood Cancer United. Shares are lower in after-market trading amid rising Treasury yields.

14.09.2026 г., 20:07 ч. UTC

Royalty Pharma PLC shares are higher today, reflecting a modest gain since Friday. Broader market concerns over rising crude oil prices may be influencing sentiment.

11.09.2026 г., 20:08 ч. UTC

Royalty Pharma PLC shares are lower today, pulling back from earlier gains amid broader market dynamics and inflation pressures influencing Federal Reserve policy.

10.09.2026 г., 23:46 ч. UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing a rise since Thursday's close, though still below the 20-day moving average.

9.09.2026 г., 20:07 ч. UTC

News

Royalty Pharma shares lower today, following a decline after Novartis' trial failure. Analysts suggest the drop may be overdone amid stable royalty expectations.

8.09.2026 г., 21:01 ч. UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting broader market dynamics despite no specific company news identified.

5.09.2026 г., 00:01 ч. UTC

News

Royalty Pharma PLC shares fell in after-market hours following the failed Phase 3 trial of pelacarsen, impacting its funding agreement with Ionis.

4.09.2026 г., 22:14 ч. UTC

Royalty Pharma PLC shares are trading lower during after-market hours, breaking a trend of higher daily closes. No specific news was identified for the decline.

3.09.2026 г., 23:05 ч. UTC

Royalty Pharma PLC shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

2.09.2026 г., 23:06 ч. UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting a slight decline since Wednesday's close, despite earlier recovery attempts.

1.09.2026 г., 20:09 ч. UTC

Royalty Pharma PLC is rising as strength in the pharmaceuticals sub-sector boosts shares. The stock remains near its one-month high despite a recent pullback.

31.08.2026 г., 23:16 ч. UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting positive market sentiment. The stock remains near the upper end of its one-month trading range.

28.08.2026 г., 20:07 ч. UTC

Royalty Pharma PLC shares are lower today amid broader market declines and rising U.S. Treasury yields, reflecting ongoing volatility in the pharmaceuticals sector.

27.08.2026 г., 23:11 ч. UTC

Royalty Pharma PLC shares are higher in after-market trading, supported by a favorable performance backdrop and positioning above the 20-day moving average.

26.08.2026 г., 23:16 ч. UTC

Royalty Pharma PLC shares are higher in after-market trading, currently above their 20-day moving average and near the upper end of their one-month range.

25.08.2026 г., 20:07 ч. UTC

Royalty Pharma PLC shares are higher today, continuing an upward trend since Monday. Lower Treasury yields are supporting investor sentiment in the market.

24.08.2026 г., 20:06 ч. UTC

Royalty Pharma PLC shares are near unchanged as market sentiment is influenced by rising oil prices and geopolitical tensions from new U.S. sanctions against Iran.

21.08.2026 г., 19:26 ч. UTC

Royalty Pharma PLC shares are higher, reflecting a broader rebound in U.S. stocks amid economic uncertainties and rising inflation. The asset remains above its 20-day moving average.

20.08.2026 г., 23:11 ч. UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline from earlier in the session amid mixed broader market sentiment.

19.08.2026 г., 20:02 ч. UTC

Royalty Pharma PLC shares are higher today, driven by strong investor interest in pharmaceuticals and unusually high market volume during regular trading hours.

18.08.2026 г., 23:21 ч. UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing an upward trend from previous sessions. No specific news was identified for this movement.

17.08.2026 г., 19:36 ч. UTC

Royalty Pharma PLC shares are trading higher during Monday's session, recovering from an earlier dip and remaining above the 20-day moving average.

15.08.2026 г., 00:01 ч. UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a routine decline since Friday's close amid mixed global equity market performance.

14.08.2026 г., 19:46 ч. UTC

Event
Social Media

Royalty Pharma PLC declared a $0.235 per share dividend today, with shares advancing since Thursday's close and near the upper end of their one-month range.

13.08.2026 г., 20:02 ч. UTC

Social Media

Royalty Pharma PLC shares are lower amid a $100 million royalty agreement with Zealand Pharma for rusfertide rights, reflecting unusual trading activity.

12.08.2026 г., 20:01 ч. UTC

Royalty Pharma PLC shares are higher today, supported by a broader market trend of gains since Tuesday. The stock is seeing unusually high trading volume.

11.08.2026 г., 19:56 ч. UTC

Royalty Pharma PLC shares are trading higher, reaching a session high earlier today. No specific news was identified to explain the price movement.

Сравнение с други в отрасъла

Ценова промяна

Royalty Pharma PLC (Class A) Прогноза

Ценова цел

By TipRanks

12.51% нагоре

12-месечна прогноза

Среден 65.714 USD  12.51%

Висок 70 USD

Нисък 62 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Royalty Pharma PLC (Class A) през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

7

Купи

0

Задържане

0

Продай

Настроение

By Acuity

7 / 339 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.